Bruce Bornstein, MD
Radiation Oncology · Fitchburg, MANPI 1770581308
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $565 and has fallen 81.5% since, to $105 in 2025.
Across 54 payments — averaging $26.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$284
- Boston Scientific$187
- Bayer$122
- Exelixis Inc.$106
- Eisai Inc.$100
- AstraZeneca$98
- plus $556 from 15 others
What the payments were for
- Food & beverage$1,455100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 14 | $284 |
| Boston Scientific | 4 | $187 |
| Bayer | 4 | $122 |
| Exelixis Inc. | 3 | $106 |
| Eisai Inc. | 4 | $100 |
| AstraZeneca | 4 | $98 |
| Astellas Pharma US Inc | 3 | $70 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $60 |
| AbbVie | 2 | $55 |
| E.r. Squibb & Sons, L.L.C. | 2 | $51 |
| Progenics Pharmaceuticals, Inc. | 1 | $44 |
| Mirati Therapeutics, Inc. | 1 | $40 |
| Accuray Incorporated | 2 | $38 |
| GSK | 1 | $35 |
| Seagen Inc. | 1 | $30 |
| Visionrt, Inc. | 1 | $29 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Sobi, Inc | 1 | $25 |
| Bioprotect Medical, Inc. | 1 | $23 |
| Bristol Myers Squibb | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
How this compares
$1,455 in reported general payments places this provider in the 75th percentile of 200 radiation oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other radiation oncology in Fitchburg
- Peter OrioBoston$1.8M
- Paul NguyenBoston$721K
- Jason EfstathiouBoston$156K
- Jonathan SchoenfeldBoston$53K
- Martin KingBoston$37K
- Raymond MakBoston$36K
- Shannon MacdonaldBoston$33K
- Nima AghdamBoston$29K
- Rachel JimenezBoston$28K
- Andrea McKeeBurlington$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.